BNP Paribas Financial Markets boosted its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 206.1% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 153,250 shares of the biopharmaceutical company's stock after buying an additional 103,186 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.13% of Catalyst Pharmaceuticals worth $3,047,000 as of its most recent filing with the SEC.
Other large investors have also recently bought and sold shares of the company. Arizona State Retirement System lifted its position in shares of Catalyst Pharmaceuticals by 2.2% in the second quarter. Arizona State Retirement System now owns 29,733 shares of the biopharmaceutical company's stock valued at $461,000 after acquiring an additional 654 shares in the last quarter. GAMMA Investing LLC raised its stake in Catalyst Pharmaceuticals by 62.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company's stock valued at $35,000 after purchasing an additional 681 shares during the last quarter. XTX Topco Ltd lifted its holdings in Catalyst Pharmaceuticals by 7.5% in the 2nd quarter. XTX Topco Ltd now owns 11,134 shares of the biopharmaceutical company's stock valued at $172,000 after purchasing an additional 773 shares in the last quarter. Sei Investments Co. boosted its stake in shares of Catalyst Pharmaceuticals by 1.3% during the 2nd quarter. Sei Investments Co. now owns 84,458 shares of the biopharmaceutical company's stock worth $1,308,000 after purchasing an additional 1,098 shares during the last quarter. Finally, Louisiana State Employees Retirement System boosted its stake in shares of Catalyst Pharmaceuticals by 2.2% during the 2nd quarter. Louisiana State Employees Retirement System now owns 56,500 shares of the biopharmaceutical company's stock worth $875,000 after purchasing an additional 1,200 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company's stock.
Insider Transactions at Catalyst Pharmaceuticals
In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 12,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total transaction of $272,640.00. Following the transaction, the insider now directly owns 51,391 shares of the company's stock, valued at $1,167,603.52. The trade was a 18.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Molly Harper sold 17,500 shares of the business's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total transaction of $385,000.00. The disclosure for this sale can be found here. Company insiders own 11.00% of the company's stock.
Catalyst Pharmaceuticals Stock Performance
Shares of CPRX traded up $0.32 during trading hours on Friday, hitting $22.02. The stock had a trading volume of 535,828 shares, compared to its average volume of 1,179,348. The company's fifty day simple moving average is $21.45 and its 200 day simple moving average is $18.95. Catalyst Pharmaceuticals, Inc. has a 12-month low of $13.00 and a 12-month high of $24.27. The firm has a market cap of $2.63 billion, a P/E ratio of 18.66, a P/E/G ratio of 3.31 and a beta of 0.75.
Analyst Ratings Changes
A number of equities analysts have recently weighed in on CPRX shares. Truist Financial boosted their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a "buy" rating in a research report on Monday, November 11th. Stephens assumed coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an "overweight" rating and a $35.00 price target on the stock. StockNews.com upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, August 9th. Citigroup upped their target price on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a "buy" rating in a research note on Friday, August 9th. Finally, HC Wainwright reiterated a "buy" rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $31.14.
Get Our Latest Analysis on CPRX
About Catalyst Pharmaceuticals
(
Free Report)
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Featured Stories
Before you consider Catalyst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalyst Pharmaceuticals wasn't on the list.
While Catalyst Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
